Lucatumumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Lucatumumab" in English language version.

refsWebsite

Global rank English rank

572^nd place

436^th place

2^nd place

2^nd place

2web.archive.org

1^st place

1^st place

4^th place

4^th place

1semanticscholar.org

11^th place

8^th place

274^th place

309^th place

1businesswire.com

615^th place

407^th place

1bloodjournal.org

low place

low place

5^th place

5^th place

1thepharmaletter.com

low place

low place

166^th place

121^st place

low place

low place

1,684^th place

1,350^th place

bloodjournal.org (Global: low place; English: low place)

Weng WK, Tong X, Luqman M, Levy R (16 November 2004). "(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma". Blood. 104 (11): 3279. doi:10.1182/blood.V104.11.3279.3279. ISSN 0006-4971.

businesswire.com (Global: 615^th place; English: 407^th place)

"Press release: XOMA and Chiron Announce Preclinical Data Presentations on CHIR-12.12 at American Hematology Conference". XOMA and Chiron vis Businesswire. December 2, 2004.

cancer.gov (Global: 1,684^th place; English: 1,350^th place)

"Lucatumumab". NCI Drug Dictionary. U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute (NCI). 2011-02-02. Retrieved 20 February 2017.

doi.org (Global: 2^nd place; English: 2^nd place)

Hassan SB, Sørensen JF, Olsen BN, Pedersen AE (April 2014). "Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials". Immunopharmacology and Immunotoxicology. 36 (2): 96–104. doi:10.3109/08923973.2014.890626. PMID 24555495. S2CID 21840914.
Weng WK, Tong X, Luqman M, Levy R (16 November 2004). "(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma". Blood. 104 (11): 3279. doi:10.1182/blood.V104.11.3279.3279. ISSN 0006-4971.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Hassan SB, Sørensen JF, Olsen BN, Pedersen AE (April 2014). "Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials". Immunopharmacology and Immunotoxicology. 36 (2): 96–104. doi:10.3109/08923973.2014.890626. PMID 24555495. S2CID 21840914.

sec.gov (Global: 572^nd place; English: 436^th place)

"Chiron and Xoma in MAb deal - Pharmaceutical industry news". The Pharma Letter. March 8, 2004.. Part of Xoma's 10-K filed 2004-03-15. Index page at SEC Edgar.
"Exhibit 10.50: Agreement, dated Feb 27, 2004, by and btwn Chiron Corp and XOMA". Xoma via SEC Edgar.
"Exhibit 10.2 Amended Research, Development and Commercialization Agreement". www.sec.gov. Xoma via SEC Edgar. May 26, 2005.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Hassan SB, Sørensen JF, Olsen BN, Pedersen AE (April 2014). "Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials". Immunopharmacology and Immunotoxicology. 36 (2): 96–104. doi:10.3109/08923973.2014.890626. PMID 24555495. S2CID 21840914.

sfgate.com (Global: 166^th place; English: 121^st place)

Tansey B (November 1, 2005). "Novartis to buy Chiron / Swiss pharmaceutical giant to pay $5.1 billion". San Francisco Chronicle.

springer.com (Global: 274^th place; English: 309^th place)

adisinsight.springer.com

"Lucatumumab". AdisInsight. Retrieved 20 February 2017.

thepharmaletter.com (Global: low place; English: low place)

"Chiron and Xoma in MAb deal - Pharmaceutical industry news". The Pharma Letter. March 8, 2004.. Part of Xoma's 10-K filed 2004-03-15. Index page at SEC Edgar.

web.archive.org (Global: 1^st place; English: 1^st place)

Statement On A Nonproprietary Name Adopted By The USAN Council – Lucatumumab, American Medical Association.
"Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)". Xoma. November 10, 2008. Archived from the original on February 20, 2017. Retrieved February 20, 2017.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Weng WK, Tong X, Luqman M, Levy R (16 November 2004). "(Poster Session No. 627-II) A Fully Human Anti-CD40 Antagonistic Antibody, CHIR-12.12, Inhibit the Proliferation of Human B Cell Non-Hodgkin's Lymphoma". Blood. 104 (11): 3279. doi:10.1182/blood.V104.11.3279.3279. ISSN 0006-4971.

xoma.com (Global: low place; English: low place)

investors.xoma.com

"Press Release: XOMA Restructures Drug Development Collaboration Including Oncology Drug Candidate HCD122 (NASDAQ:XOMA)". Xoma. November 10, 2008. Archived from the original on February 20, 2017. Retrieved February 20, 2017.